SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TOANTI-TNF THERAPY: 52-WEEK RESULTS FROM TWO INTERNATIONAL PHASE 3 TRIALS

被引：0
|
作者：
Deodhar, Atul [1 ]
Baeten, Dominique [2 ]
Blanco, Ricardo [3 ]
Sieper, Joachim [4 ]
Martin, Ruvie [5 ]
Porter, Brian [5 ]
Richards, Hanno [6 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Univ Amsterdam, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[3] Hosp Marques Valdecilla, Madrid, Spain
[4] Charite Univ Med Berlin, Berlin, Germany
[5] Novartis Pharmaceut, New York, NY USA
[6] Novartis Pharma AG, Basel, Switzerland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2016年 / 22卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3287369
引用
收藏
页码：137 / 138
页数：2
相关论文
共 42 条
  • [1] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: 52-WEEK RESULTS FROM AN INTERNATIONAL PHASE 3 TRIAL
    Kavanaugh, Arthur
    Kivitz, Alan
    McInnes, Iain B.
    Mease, Philip
    Mpofu, Shephard
    Wang, Zailong
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 141 - 142
  • [2] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials
    Baeten, Dominique
    Blanco, Ricardo
    Geusens, Piet
    Sieper, Joachim
    Tseng Jui-Cheng
    Martin, Ruvie
    Porter, Brian
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [3] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: 52-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL WITH SUBCUTANEOUS DOSING
    Hall, Stephen
    Kavanaugh, Arthur
    McInnes, Iain
    Mease, Philip
    Chinoy, Hector
    Kivitz, Alan
    Patekar, Manmath
    Wang, Z.
    Mpofu, Shephard
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 38 - 39
  • [4] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing
    Kavanaugh, Arthur
    McInnes, Iain B.
    Mease, Philip J.
    Hall, Stephan
    Chinoy, Hector
    Kivitz, Alan J.
    Patekar, Manmath
    Wang, Zailong
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [5] Secukinumab provides sustained improvements in the signs and symptoms of Active Psoriatic Arthritis in Anti. TNF-Naive patients and those previously exposed to Anti-TNF Therapy: 52-week results from a randomized, double-blind, placebo-controlled phase 3 trial with subcutaneous dosing
    Hall, S.
    Kavanaugh, A.
    McInnes, I.
    Mease, P.
    Chinoy, H.
    Kivitz, A.
    Patekar, M.
    Wang, Z.
    Mpofu, S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 53 - 53
  • [6] SECUKINUMAB EFFICACY IN ANTI-TNF-NAIVE PATIENTS AND PATIENTS PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY (MEASURE 2) IN ACTIVE ANKYLOSING SPONDYLITIS
    Sieper, J.
    Braun, J.
    Baraliakos, X.
    Baeten, D. L.
    Dougados, M.
    Emery, P.
    Deodhar, A.
    Porter, B.
    Andersson, M.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 272 - 272
  • [7] Secukinumab Efficacy in Anti-TNF-Naive Patients and Patients Previously Exposed to Anti-TNF Therapy: Results of A Randomized, Double-Blind, Placebo- Controlled Phase 3 Study (MEASURE 2) in Active Ankylosing Spondylitis
    Jean, Dudler
    Braun, J.
    Baraliakos, X.
    Baeten, D.
    Dougados, M.
    Emery, P.
    Deodhar, A.
    Porter, B.
    Andersson, M.
    Richards, H.
    SWISS MEDICAL WEEKLY, 2016, 146 : 7S - 7S
  • [8] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 STUDY
    Pavelka, K.
    Kivitz, A. J.
    Blanco, R.
    Maradiaga, M.
    Tahir, H.
    Slade, A.
    Wang, Y.
    Rohrer, S.
    Porter, B.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S107 - S108
  • [9] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study
    Pavelka, Karel
    Kivitz, Alan J.
    Dokoupilova, Eva
    Blanco, Ricardo
    Maradiaga, Marco
    Tahir, Hasan
    Slade, Alan
    Wang, Yi
    Rohrer, Susanne
    Porter, Brian
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [10] NETAKIMAB EFFICACY IN ANTI-TNF-NAIVE AND ANTI-TNF-EXPERIENCED PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA TRIAL
    Erdes, S.
    Mazurov, V.
    Dubinina, T.
    Gaydukova, I.
    Kundzer, A.
    Soroka, N.
    Eremeeva, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 726 - 727
12345